Mukka Proteins FY26 Revenue Surges 44% to ₹1,449.5 Crore; PAT Up 18.7%
Mukka Proteins reported FY26 consolidated revenue of ₹1,449.5 crore, up 44% YoY. EBITDA rose 30.9% to ₹145.3 crore and PAT increased 18.7% to ₹57.1 crore. Q4 FY26 saw revenue at ₹380.6 crore with PAT up 52.6% YoY to ₹21.4 crore. The company is expanding in Oman and Sri Lanka and secured a waste management contract.
The significant financial growth and strategic international expansion indicate a substantial positive impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for both the full fiscal year and the fourth quarter, along with positive strategic expansion updates.
Mukka Proteins Limited announced its audited Financial Results for the Quarter and Year ended March 31, 2026. For the full fiscal year FY26, the company reported a consolidated revenue from operations of ₹1,449.5 crore, marking a significant year-on-year increase of 44.0%. The consolidated EBITDA for FY26 stood at ₹145.3 crore, up 30.9% YoY, with an EBITDA margin of 10.0%. Profit After Tax (PAT) for FY26 was ₹57.1 crore, an 18.7% increase YoY, with a PAT margin of 3.9%. This strong performance was attributed to robust demand, an improved pricing environment, and disciplined operational execution, benefiting from favorable global fishmeal demand-supply dynamics.
In the fourth quarter of FY26 (Q4 FY26), revenue from operations reached ₹380.6 crore. EBITDA for the quarter increased by 48.0% YoY to ₹49.2 crore, with the EBITDA margin improving by 421 basis points to 12.9%. PAT for Q4 FY26 was ₹21.4 crore, up 52.6% YoY, and the PAT margin rose by 194 basis points to 5.6%, reflecting improved operational efficiencies and favorable realizations.
Key strategic developments include receiving confirmation from Global Trust Certification (NSF) for alignment with the MarinTrust Improver Programme, strengthening sustainable sourcing practices. The company is also expanding its international capacity with a new facility in Oman, expected to commence operations in the coming quarters. Furthermore, the Board has approved the incorporation and investment in "Lanka Bio Proteins Private Limited" in Sri Lanka, marking a step towards geographical diversification. Mukka Proteins has also secured a contract from BBMP/BSWML for integrated animal waste management in Bengaluru.
Mr. Kalandan Mohammed Haris, CEO & MD, expressed confidence in the company's strategic initiatives, including the Oman and Sri Lanka expansions, positioning them well to scale operations and strengthen their global footprint. He highlighted the positive industry dynamics and continued focus on cost optimization and sustainable sourcing.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under annual results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.